The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CCRIS 5161     azane; platinum(+2) cation; dichloride

Synonyms: HSDB 3940, AR-1I4195, LS-117696, AKOS015853703, NSC 131558, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Platidiam


Psychiatry related information on Platidiam


High impact information on Platidiam


Chemical compound and disease context of Platidiam


Biological context of Platidiam


Anatomical context of Platidiam


Associations of Platidiam with other chemical compounds


Gene context of Platidiam


Analytical, diagnostic and therapeutic context of Platidiam

  • Hence, by preventing EGFR-mediated survival signaling, the internalization route we uncovered enhances the cytotoxic effect of drugs like cis-platinum, which may underlie interactions between chemotherapy and EGFR-targeting drugs [37].
  • A monoclonal antibody raised against trans-DDP-DNA was competitively inhibited in an ELISA by 40 nM trans-DDP bound to DNA, (D/N)b = 0.022 [38].
  • The cells were treated with cis-dichlorodiammineplatinum and solubilized in NaDodSO4-containing buffer, and the DNA was pelleted by high-speed centrifugation [39].
  • The interaction of cis-diamminedichloroplatinum(II) (c-DDP) with daily fractionated radiotherapy was studied in the SCCVII tumor, the duodenum, and the lungs of C3H/Km mice [40].
  • After this period, as happened also with nodules treated with 5-FUra alone, vigorous regrowth occurred after treatment with cis-DDP plus 5-FUra, and all the nodules regained the size of the controls sooner or later [41].


  1. Virilizing hepatoblastoma: precocious sexual development and partial response of pulmonary metastases to cis-platinum. Arshad, R.R., Woo, S.Y., Abbassi, V., Hoy, G.R., Sinks, L.F. CA: a cancer journal for clinicians. (1982) [Pubmed]
  2. alpha-Difluoromethylornithine-induced polyamine depletion of 9L tumor cells modifies drug-induced DNA cross-link formation. Tofilon, P.J., Deen, D.F., Marton, L.J. Science (1983) [Pubmed]
  3. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. Vandier, D., Calvez, V., Massade, L., Gouyette, A., Mickley, L., Fojo, T., Rixe, O. J. Natl. Cancer Inst. (2000) [Pubmed]
  4. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. Alberts, D.S., Peng, Y.M., Chen, H.S., Moon, T.E., Cetas, T.C., Hoeschele, J.D. J. Natl. Cancer Inst. (1980) [Pubmed]
  5. Letter: Allergic reactions to cis platinum. Von Hoff, D.D., Slavik, M., Muggia, F.M. Lancet (1976) [Pubmed]
  6. Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. Leopold, W.R., Batzinger, R.P., Miller, E.C., Miller, J.A., Earhart, R.H. Cancer Res. (1981) [Pubmed]
  7. A pilot study of lorazepam-induced amnesia with cis-platinum-containing chemotherapy. Semrad, N.F., Leuchter, R.S., Townsend, D.E., Wade, M.E., Lagasse, L.D. Gynecol. Oncol. (1984) [Pubmed]
  8. cis-platinum ototoxicity in children. Pasic, T.R., Dobie, R.A. Laryngoscope (1991) [Pubmed]
  9. Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. Rebert, C.S., Pryor, G.T., Frick, M.S. Journal of applied toxicology : JAT. (1984) [Pubmed]
  10. Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Ji, S.K., Park, N.H., Choi, H.M., Kim, Y.W., Lee, S.H., Lee, K.H., Ahn, S.Y., Lee, S.U., Han, B.H., Park, B.C. Korean J. Intern. Med. (1996) [Pubmed]
  11. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Teicher, B.A., Herman, T.S., Holden, S.A., Wang, Y.Y., Pfeffer, M.R., Crawford, J.W., Frei, E. Science (1990) [Pubmed]
  12. Overexpression of metallothionein confers resistance to anticancer drugs. Kelley, S.L., Basu, A., Teicher, B.A., Hacker, M.P., Hamer, D.H., Lazo, J.S. Science (1988) [Pubmed]
  13. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Sherman, S.E., Gibson, D., Wang, A.H., Lippard, S.J. Science (1985) [Pubmed]
  14. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Byun, T.S., Pacek, M., Yee, M.C., Walter, J.C., Cimprich, K.A. Genes Dev. (2005) [Pubmed]
  15. Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. Khandekar, J.D., Elson, P.J., DeWys, W.D., Slayton, R.E., Harris, D.T. J. Clin. Oncol. (1985) [Pubmed]
  16. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer. Osoba, D., Rusthoven, J.J., Turnbull, K.A., Evans, W.K., Shepherd, F.A. J. Clin. Oncol. (1985) [Pubmed]
  17. Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice. Dykes, D.J., Waud, W.R., Harrison, S.D., Laster, W.R., Griswold, D.P., Shealy, Y.F., Montgomery, J.A. Cancer Res. (1989) [Pubmed]
  18. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Feng, W.H., Israel, B., Raab-Traub, N., Busson, P., Kenney, S.C. Cancer Res. (2002) [Pubmed]
  19. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. Jaffe, N., Robertson, R., Ayala, A., Wallace, S., Chuang, V., Anzai, T., Cangir, A., Wang, Y.M., Chen, T. J. Clin. Oncol. (1985) [Pubmed]
  20. Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding? LeRoy, A.F., Thompson, W.C. J. Natl. Cancer Inst. (1989) [Pubmed]
  21. Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II). Nishio, K., Sugimoto, Y., Fujiwara, Y., Ohmori, T., Morikage, T., Takeda, Y., Ohata, M., Saijo, N. J. Clin. Invest. (1992) [Pubmed]
  22. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA. Yaneva, J., Leuba, S.H., van Holde, K., Zlatanova, J. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  23. Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II). Mascharak, P.K., Sugiura, Y., Kuwahara, J., Suzuki, T., Lippard, S.J. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  24. Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. Howard, G.C., Misra, U.K., DeCamp, D.L., Pizzo, S.V. J. Clin. Invest. (1996) [Pubmed]
  25. Identification of semaphorin E as a non-MDR drug resistance gene of human cancers. Yamada, T., Endo, R., Gotoh, M., Hirohashi, S. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  26. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H., Poirier, M.C. Proc. Natl. Acad. Sci. U.S.A. (1987) [Pubmed]
  27. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II). Toney, J.H., Donahue, B.A., Kellett, P.J., Bruhn, S.L., Essigmann, J.M., Lippard, S.J. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  28. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. Ikuno, N., Soda, H., Watanabe, M., Oka, M. J. Natl. Cancer Inst. (1995) [Pubmed]
  29. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Treiber, D.K., Zhai, X., Jantzen, H.M., Essigmann, J.M. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  30. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Duckett, D.R., Drummond, J.T., Murchie, A.I., Reardon, J.T., Sancar, A., Lilley, D.M., Modrich, P. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  31. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Borch, R.F., Pleasants, M.E. Proc. Natl. Acad. Sci. U.S.A. (1979) [Pubmed]
  32. SAPK2/p38-dependent F-actin reorganization regulates early membrane blebbing during stress-induced apoptosis. Huot, J., Houle, F., Rousseau, S., Deschesnes, R.G., Shah, G.M., Landry, J. J. Cell Biol. (1998) [Pubmed]
  33. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Husain, A., He, G., Venkatraman, E.S., Spriggs, D.R. Cancer Res. (1998) [Pubmed]
  34. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. Hayakawa, J., Ohmichi, M., Kurachi, H., Ikegami, H., Kimura, A., Matsuoka, T., Jikihara, H., Mercola, D., Murata, Y. J. Biol. Chem. (1999) [Pubmed]
  35. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Inoue, J., Otsuki, T., Hirasawa, A., Imoto, I., Matsuo, Y., Shimizu, S., Taniwaki, M., Inazawa, J. Am. J. Pathol. (2004) [Pubmed]
  36. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. Hayakawa, J., Depatie, C., Ohmichi, M., Mercola, D. J. Biol. Chem. (2003) [Pubmed]
  37. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. Zwang, Y., Yarden, Y. EMBO J. (2006) [Pubmed]
  38. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II). Sundquist, W.I., Lippard, S.J., Stollar, B.D. Proc. Natl. Acad. Sci. U.S.A. (1987) [Pubmed]
  39. Association of cytokeratin p39 with DNA in intact Novikoff hepatoma cells. Ward, W.S., Schmidt, W.N., Schmidt, C.A., Hnilica, L.S. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  40. Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cis-diamminedichloroplatinum (II) in C3H/Km mouse model systems. Kanazawa, H., Rapacchietta, D., Kallman, R.F. Cancer Res. (1988) [Pubmed]
  41. Effects of combined treatments of cis-diamminedichloroplatinum(II), 5-fluorouracil, and X-rays on growth of human cancer nodules maintained in continuous organotypic culture. Beaupain, R., Dionet, C. Cancer Res. (1985) [Pubmed]
WikiGenes - Universities